HRT: Follow up of WHI, HERS II and other meta-analysis. Is still the dream alive?;Traitement hormonal substitutif de la ménopause: Les suites de la WHI, HERS II, et autres méta-analyses: Le rêve est-il brisé?

References en Gynecologie Obstetrique

Volumn 9, Issue 1, 2002, Pages 11-13

  Bouchard, P ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTROGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO; PROGESTERONE;

ADULT; AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDITORIAL; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE; META ANALYSIS; RISK BENEFIT ANALYSIS;

EID: 0036818536     PISSN: 12448168     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (14)

1. Stampfer MO, Colditz GA (2002) Estrogen Replacement Therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Ann Intern Med 137: 290
2. Mendelsohn ME, Kanas RH (1999) The protective effects of estrogen on the cardiovascular System. N Engl J Med 340: 1801-1811
3. Halley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post menopausal women (HERS Study). JAMA 280: 605-613
4. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghof E, Wenger N for the HERS Research Group (2002) Cardiovascular disease outcomes during 6.8 years of HRT. Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II)). JAMA 288: 49-57
5. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk Gj, Stuckey TD, Rogers WJ, Givens DH, Waters D (2000) Effects of estrogen replacement on the progression of coronary atherosclerosis. N Engl J Med 343: 522-529
6. Writing Group for the Women's Health Initiative (2002) Risks and benefits of estrogen plus progestin in healthy post women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 352-333
7. Enserink M (2002) The vanishing promises of Hormone Replacement Therapy. Science 297: 325-326
8. Harris ST, Eriksen EF, Davidson M, Ettinger MP, Moffett Jr AH, Baylink DD, Crusan CE, Chines AA (2001) Effect of Continued risedronate and HRT on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 86: 1890-1897
9. Mosca L, Collins P, Herrington DM, Mendelsohn ME, Pasternak RC, Robertson RM, Schenck-Gustafsson K, Smith SC, Taubert KA, Wenger NK (2001) HRT and cardiovascular disease: a Statement for Healthcare Professionals from the America Heart Association. Circulation 104: 499-503
10. HD Nelson, Humphrey LL, Nygren P, Teutsch SM, Allan JD (2002) Postmenopausal Hormone Replacement therapy. A scientific review. JAMA 288: 872-881
11. Laine C (2002) Postmenopausal Hormone Replacement Therapy. How could we have been so wrong. Ann Intern Med 137: 290
12. Humphrey LL, Chan BKS, Sox HC (2002) Postmenopausal Hormone Replacement Therapy and the primary prevention of cardiovascular disease. Ann Intern Med 137: 273-284
13. Rau SW, Büttner M (2001) Neuroprotective effect of estrogen: new insights into mechanisms of action. Endocrinology 142: 969-973
14. Herrington DM, Howard TD, Hawkin GA, Reboussin DM, Xu J, Zheng SL, Brosnihan KB, Meyers DA, Bleecker ER (2002) Estrogen receptor polymorphisms and effects of estrogen replacement on HDLc in women with coronary disease. N Engl J Med 346: 967-974